drugset / Trial / NCT03069001

Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV

NCT03069001

Phase 4 Completed 90 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective study was conducted at Ain Shams University Hospital, Internal Medicine, Hepatology and Gastroenterology Department, and Tropical Medicine Department. To compare the efficacy of the combination of sofosbuvir and simeprevir for 12 weeks with the combination of sofosbuvir and ribavirin for 24 weeks in Egyptian patients with HCV-related Child A cirrhosis.

Timeline

Start
2015-06
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ribavirin Small molecule 1000 mg Oral
Comparator Ribavirin Small molecule 1200 mg Oral
Comparator Simeprevir Small molecule 150 mg Oral
Comparator Sofosbuvir Small molecule 400 mg Oral